ArticleThe Journal of infectious diseases2016
Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03025074 (Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Skin cancer in patients who are co-infected with HIV/ HBV or HIV/HCV: a systematic review.Archives of dermatological research · 2024Pooled it
- Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study.BMC infectious diseases · 2026Article
- Aspartate aminotransferase-to-platelet ratio index (APRI) for staging of fibrosis in adults with chronic hepatitis C.The Cochrane database of systematic reviews · 2025Article
- Circulating chemokine levels and receptor polymorphisms have potential as biomarkers for fibrosis stages in patients with chronic hepatitis C infection.Molecular biology reports · 2025Article
- Distribution and inflammatory potential of hepatitis C virus genotypes in the United States, 2011-2020.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Cost-effectiveness analysis of emergency department-based hepatitis C screening and linkage-to-care program.BMC health services research · 2024Article
- Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy.Biomedical reports · 2024Article
- Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.Microorganisms · 2024Review
- A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.CPT: pharmacometrics & systems pharmacology · 2023Article
- A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.Frontiers in immunology · 2021Review
- Machine learning models to predict disease progression among veterans with hepatitis C virus.PloS one · 2019Article
- Epidemiology of Hepatitis C.Clinical liver disease · 2018Review
- Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care.JMIR research protocols · 2018Article
- Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients.Medical microbiology and immunology · 2018Article
- Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Addictive disorders & their treatment · 2017Article
- Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.Current opinion in gastroenterology · 2017Review
- Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.Arthritis research & therapy · 2017Article
- Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1.Open forum infectious diseases · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundFibrosis progression varies markedly in hepatitis C virus (HCV)-infected individuals. We investigated factors that influence fibrosis progression in chronic HCV infection.
methodsHCV-infected patients who underwent at least 2 liver biopsies were included in this study. Associations between fibrosis progression and epidemiologic, virologic, and disease-associated factors were analyzed using logistic regression and multistate Markov modeling.
resultsWe analyzed 936 biopsy specimens obtained from 378 individuals. Mean age (±SD) at first biopsy was 48.3 ± 9.3 years, 59.3% of patients were male, 59.9% were white, and 86.7% were infected with HCV genotype 1. Fibrosis progression and cirrhosis occurred in 57.4% and 5.8%, respectively. Fibrosis progression between the first and last biopsies was associated with lower fibrosis in the first biopsy specimen (P < .001) and with the occurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007). We found the highest fibrosis progression rate between stages 0 and 1 and the lowest between stages 2 and 3. Increased necroinflammation and higher ALT level were associated with faster progression. HCV genotype 3-infected patients were more likely to progress to cirrhosis (P < .001).
conclusionsFibrosis progression in HCV is not linear but varies according to stage, with the highest progression in patients with the lowest fibrosis severity. Patients who experience flares in the ALT level are also more likely to progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.